Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | STAT6 | P42226 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555868 | 1.00 | EPHX2 (0.32) | EPHX2FFAR3MAPK1TP53NFKB1 | |
| SCHEMBL6826810 | 1.00 | EPHX2 (0.32) | EPHX2FFAR3MAPK1TP53NFKB1 | |
| SCHEMBL11817461 | 0.83 | HTT (0.34) | EPHX2FFAR3MAPK1CYP2C19THPO | |
| SCHEMBL12942820 | 0.83 | HTT (0.34) | EPHX2FFAR3MAPK1CYP2C19THPO | |
| SCHEMBL2694749 | 0.81 | — | — | |
| SCHEMBL25202301 | 0.81 | SMYD3 (0.33) | FFAR3 | |
| SCHEMBL16293737 | 0.81 | SMYD3 (0.33) | FFAR3 | |
| SCHEMBL25198840 | 0.81 | SMYD3 (0.33) | FFAR3 | |
| SCHEMBL22169752 | 0.78 | ALDH1A1 (0.31) | — | |
| SCHEMBL2576395 | 0.78 | OPRL1 (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825313-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210047304-A1 | Bromodomain Inhibitors | ABBVIE INC. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047304-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | EPHX2 2654/4885FFAR3 2812/4885MAPK1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.